Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387573397> ?p ?o ?g. }
- W4387573397 endingPage "2450" @default.
- W4387573397 startingPage "2450" @default.
- W4387573397 abstract "Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a significant negative impact on the quality of life of patients. To date, the therapeutic landscape for the management of the disease has been extremely limited, resulting in a profound unmet need. Indeed, adalimumab, an anti-tumor necrosis factor (TNF)-α monoclonal antibody, is the only approved biologic agent for HS, obtaining a therapeutic response in only 50% of HS patients. Numerous clinical trials are currently ongoing to test novel therapeutic targets in HS. The IL-17-mediated cascade is the target of several biologic agents that have shown efficacy and safety in treating moderate-to-severe HS. Both bimekizumab and secukinumab, targeting IL-17 in different manners, have successfully completed phase III trials with promising results; the latter has recently been approved by EMA for the treatment of HS. The aim of this review is to summarize the current state of knowledge concerning the relevant role of IL-17 in HS pathogenesis, highlighting the key clinical evidence of anti-IL-17 agents in the treatment of this disease." @default.
- W4387573397 created "2023-10-13" @default.
- W4387573397 creator A5006731288 @default.
- W4387573397 creator A5017062027 @default.
- W4387573397 creator A5021076756 @default.
- W4387573397 creator A5045966797 @default.
- W4387573397 creator A5074904135 @default.
- W4387573397 creator A5075131381 @default.
- W4387573397 creator A5086374140 @default.
- W4387573397 date "2023-10-11" @default.
- W4387573397 modified "2023-10-13" @default.
- W4387573397 title "IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa" @default.
- W4387573397 cites W1493141693 @default.
- W4387573397 cites W1825622469 @default.
- W4387573397 cites W1905011311 @default.
- W4387573397 cites W1928646564 @default.
- W4387573397 cites W1973670195 @default.
- W4387573397 cites W1996601924 @default.
- W4387573397 cites W1997469498 @default.
- W4387573397 cites W2004186675 @default.
- W4387573397 cites W2020760332 @default.
- W4387573397 cites W2025447458 @default.
- W4387573397 cites W2094554745 @default.
- W4387573397 cites W2103018315 @default.
- W4387573397 cites W2113628816 @default.
- W4387573397 cites W2115582439 @default.
- W4387573397 cites W2158854771 @default.
- W4387573397 cites W2160965670 @default.
- W4387573397 cites W2167777472 @default.
- W4387573397 cites W2170659823 @default.
- W4387573397 cites W2503109448 @default.
- W4387573397 cites W2564885013 @default.
- W4387573397 cites W2694182897 @default.
- W4387573397 cites W2724412839 @default.
- W4387573397 cites W2767163492 @default.
- W4387573397 cites W2790896106 @default.
- W4387573397 cites W2903052440 @default.
- W4387573397 cites W2939946042 @default.
- W4387573397 cites W2977229878 @default.
- W4387573397 cites W3004652817 @default.
- W4387573397 cites W3022379440 @default.
- W4387573397 cites W3025940150 @default.
- W4387573397 cites W3026913959 @default.
- W4387573397 cites W3092268290 @default.
- W4387573397 cites W3130868461 @default.
- W4387573397 cites W3133173889 @default.
- W4387573397 cites W3139458741 @default.
- W4387573397 cites W3156084043 @default.
- W4387573397 cites W3176033515 @default.
- W4387573397 cites W3193189414 @default.
- W4387573397 cites W3194448077 @default.
- W4387573397 cites W3201606483 @default.
- W4387573397 cites W4205190216 @default.
- W4387573397 cites W4210992315 @default.
- W4387573397 cites W4213036339 @default.
- W4387573397 cites W4281718907 @default.
- W4387573397 cites W4281749253 @default.
- W4387573397 cites W4311026127 @default.
- W4387573397 cites W4311115611 @default.
- W4387573397 cites W4315881045 @default.
- W4387573397 cites W4319067669 @default.
- W4387573397 cites W4366174864 @default.
- W4387573397 cites W4367315810 @default.
- W4387573397 cites W4379376898 @default.
- W4387573397 cites W4385562840 @default.
- W4387573397 cites W4386767292 @default.
- W4387573397 doi "https://doi.org/10.3390/pharmaceutics15102450" @default.
- W4387573397 hasPublicationYear "2023" @default.
- W4387573397 type Work @default.
- W4387573397 citedByCount "0" @default.
- W4387573397 crossrefType "journal-article" @default.
- W4387573397 hasAuthorship W4387573397A5006731288 @default.
- W4387573397 hasAuthorship W4387573397A5017062027 @default.
- W4387573397 hasAuthorship W4387573397A5021076756 @default.
- W4387573397 hasAuthorship W4387573397A5045966797 @default.
- W4387573397 hasAuthorship W4387573397A5074904135 @default.
- W4387573397 hasAuthorship W4387573397A5075131381 @default.
- W4387573397 hasAuthorship W4387573397A5086374140 @default.
- W4387573397 hasBestOaLocation W43875733971 @default.
- W4387573397 hasConcept C126322002 @default.
- W4387573397 hasConcept C159654299 @default.
- W4387573397 hasConcept C16005928 @default.
- W4387573397 hasConcept C177713679 @default.
- W4387573397 hasConcept C17991360 @default.
- W4387573397 hasConcept C203014093 @default.
- W4387573397 hasConcept C2776002364 @default.
- W4387573397 hasConcept C2776260265 @default.
- W4387573397 hasConcept C2779134260 @default.
- W4387573397 hasConcept C2779786854 @default.
- W4387573397 hasConcept C2780132546 @default.
- W4387573397 hasConcept C2780564577 @default.
- W4387573397 hasConcept C2911221801 @default.
- W4387573397 hasConcept C535046627 @default.
- W4387573397 hasConcept C542903549 @default.
- W4387573397 hasConcept C71924100 @default.
- W4387573397 hasConceptScore W4387573397C126322002 @default.
- W4387573397 hasConceptScore W4387573397C159654299 @default.
- W4387573397 hasConceptScore W4387573397C16005928 @default.